附加益生菌治疗持续性变应性鼻炎:一项随机交叉临床试验
这项随机交叉临床试验纳入持续性变应性鼻炎患者,比较布地奈德联合益生菌与布地奈德联合安慰剂各8周(洗脱期8周)对生活质量的影响。共152例完成研究,联合益生菌组SF-36躯体与心理成分评分改善均优于单用布地奈德组,SNOT-22与CARAT评分下降也更明显。作者认为加用益生菌可显著改善生活质量,但研究人群临床情况可能不能很好代表一般变应性鼻炎人群,建议进一步研究。
要点
- 布地奈德联合益生菌8周较布地奈德联合安慰剂进一步改善持续性变应性鼻炎患者SF-36评分。
- 联合益生菌组SNOT-22与CARAT评分下降幅度均大于单用布地奈德组。
- SF-36躯体成分Cohen's d=0.40、需治疗人数=10.77;心理成分分别为0.33和12.61。
核心结论
- 在布地奈德基础上加用益生菌可显著改善持续性变应性鼻炎患者的生活质量。
- 作者指出这些患者的临床情况可能不能很好代表一般人群中的变应性鼻炎患者。
- 作者建议进一步研究。
研究设计与样本
- 随机交叉临床试验,纳入持续性变应性鼻炎患者。
- 每例受试者先接受布地奈德联合益生菌(BP)或布地奈德联合安慰剂(B)治疗8周,随后交换方案再治疗8周,中间设8周洗脱期。
- 主要结局为SF-36评分变化,次要结局采用SNOT-22和CARAT问卷评估。
- 共152例受试者完成研究,年龄30.1±7.6岁。
- 证据等级为1b。
主要发现
- 两组SF-36评分较基线均有改善,BP组疗效优于B组。
- SF-36躯体成分量表Cohen's d=0.40,需治疗人数=10.77。
- SF-36心理成分量表Cohen's d=0.33,需治疗人数=12.61。
- BP组SNOT-22和CARAT评分下降幅度均大于B组。
局限性
- 作者指出这些患者的临床情况可能不能很好代表一般人群中的变应性鼻炎患者。
- 作者建议进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Current medications for allergic rhinitis (AR) may have undesirable side effects that could affect quality of life (QoL). Probiotics could be an alternative in these patients. The aim of this study was to assess the impact of add-on probiotics on symptoms and QoL of patients. METHODS: In this randomized crossover clinical trial, patients with persistent AR were included. Each subject received budesonide with probiotic supplements (BP) or budesonide with placebo for 8 weeks (B), then vice versa for a further 8 weeks. There was an 8-week washout. The primary outcome was the change of the Short Form 36-Item Health Survey (SF-36) score. The secondary outcomes were assessed by the Sinonasal Outcome Test-22 (SNOT-22) and the Control of Allergic Rhinitis and Asthma Test (CARAT) questionnaires. RESULTS: A total of 152 subjects (30.1 ± 7.6 years) completed the study. The SF-36 score in both groups showed improvement compared with baseline values. Treatment BP was more effective than that of B. The Cohen's d and the number needed to treat for Physical Component Scales of SF-36 were 0.40 and 10.77, respectively. These values for Mental Component Scales were 0.33 and 12.61, respectively. Also, treatment BP showed more reduction in the score of SNOT-22 and CARAT. CONCLUSION: This study showed that the addition of probiotics to budesonide significantly improved QoL in persistent AR patients. However, the clinical situation of these patients may be not very representative of AR patients in general population. Further studies are recommended. LEVEL OF EVIDENCE: 1b Laryngoscope, 129:1744-1750, 2019.
引用
- Jalali MM, Soleimani R, Alavi Foumani A, et al. Add-on probiotics in patients with persistent allergic rhinitis: A randomized crossover clinical trial. Laryngoscope. 2019. PMID: 30794334. doi:10.1002/lary.27858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。